PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCarfilzomib
Carfilzomib
Carfilzomib, Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target proteasome subunit beta type-5.
Download report
Favorite
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Carfilzomib (discontinued: Carfilzomib)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
kyprolisNew Drug Application2025-06-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
CARFILZOMIB, KYPROLIS, ONYX PHARMS AMGEN
2023-08-20I-842
Patent Expiration
Patent
Expires
Flag
FDA Information
Carfilzomib, Kyprolis, Onyx Pharms Amgen
94935822033-02-27DP
RE479542029-10-21U-3449
77371122027-12-07DP
74170422026-07-20DS, DP
72328182025-04-14DS, DP
74917042025-04-14U-1260, U-2319, U-2320, U-2947
81293462025-04-14U-1260, U-2319, U-2320, U-2947
82071252025-04-14DS, DP
82071262025-04-14DP
82071272025-04-14U-1260, U-2319, U-2320, U-2947
82072972025-04-14DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XG: Proteasome inhibitors, antineoplastic agent
— L01XG02: Carfilzomib
HCPCS
Code
Description
J9047
Injection, carfilzomib, 1 mg
Clinical
Clinical Trials
264 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.01938111564
Plasma cell neoplasmsD054219——132691546
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Residual neoplasmD018365————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——34———7
LymphomaD008223—C85.972———7
NeoplasmsD009369—C8052———6
T-cell lymphomaD016399——41———4
Waldenstrom macroglobulinemiaD008258—C88.012———3
Smoldering multiple myelomaD000075122———3———3
T-cell lymphoma peripheralD016411——21———2
Lung neoplasmsD008175—C34.9022———2
Small cell lung carcinomaD055752——22———2
Neuroendocrine carcinomaD018278———1———1
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C953————3
Hematologic neoplasmsD019337——3————3
Large b-cell lymphoma diffuseD016403—C83.32————2
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.02————2
Lymphoid leukemiaD007945—C912————2
Mantle-cell lymphomaD020522—C83.12————2
Non-hodgkin lymphomaD008228—C85.92————2
TransplantationD014180——1————1
Hepatic insufficiencyD048550——1————1
Chronic kidney failureD007676EFO_0003884N18.61————1
Show 16 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCarfilzomib
INNcarfilzomib
Description
Carfilzomib is a synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma It has a role as an antineoplastic agent and a proteasome inhibitor. It is a tetrapeptide, a member of morpholines and an epoxide.
Classification
Small molecule
Drug classproteozome inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
Identifiers
PDB—
CAS-ID868540-17-4
RxCUI—
ChEMBL IDCHEMBL451887
ChEBI ID65347
PubChem CID11556711
DrugBankDB08889
UNII ID72X6E3J5AR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
5693
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
P28074
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kyprolis – Ligand Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Kyprolis – Amgen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Kyprolis – Onyx Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,062 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
22,381 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use